Hemophilia is a rare, inherited disease that causes blood to not clot as it should and can cause spontaneous bleeding. Learn how this affects your prognosis.

Treatment involved an antithrombin-based dose regimen targeting antithrombin levels between 15% and 35%, starting at 50 mg once every 2 months, individually adjusted to 20, 50, or 80 mg monthly or 20 ...

Rising Prevalence of Hemophilia, Increasing Adoption of Recombinant Therapies, and Breakthroughs in Gene Therapy Propel Market Growth.Pune, March 12, 2025 (GLOBE NEWSWIRE) -- Hemophilia Market Size & ...

“Gene therapy for hemophilia A with the use of lentiviral vector-transduced autologous HSCs resulted in stable factor VIII ...

Jammu Hemophilia Society, in collaboration with the Department of Paediatrics of Shri Maharaja Gulab Singh (SMGS) Hospital ...

The global hemophilia treatment market is on a strong growth trajectory, with projections indicating a rise from USD 12.1 billion in 2024 to a remarkable USD 18.7 billion by 2034. This growth, driven ...

It's hard watching a former local darling get restructured, but federal funding blocks and a lack of local investors are more front-of-mind.

The Government of Kerala oversees the Kerala State Lotteries program. It was founded in 1967 and is the first of its kind in ...

The future of cancer care is gene therapy."John Wrangle, M.D., a lung cancer researcher at MUSC Hollings Cancer Center, is ...

The Government of Kerala oversees the Kerala State Lotteries program. It was founded in 1967 and is the first of its kind in ...

Opens in a new tab or window Less than a year after approval, Pfizer said it plans to discontinue its hemophilia B gene therapy fidanacogene elaparvovec (Beqvez) across all global markets ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. The New York pharma is ending global development and commercialization of ...